Ligand Pharmaceuticals (LGND) Share-based Compensation (2010 - 2026)

Ligand Pharmaceuticals has reported Share-based Compensation for 16 years, with the latest figure at -$23.0 million in Q4 2025.

• Quarterly Share-based Compensation fell 158.44% year-over-year to -$23.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 97.34% YoY) and the FY2025 annual result came in at $9.6 million, down 76.64% from the prior year.
• Share-based Compensation eased to -$23.0 million in Q4 2025 per LGND's latest filing, from $14.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $39.3 million in Q4 2024 and troughed at -$31.1 million in Q4 2022.
• A 5-year average of $4.4 million and a median of $5.9 million in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation tumbled 7025.0% in 2023, then jumped 366.19% in 2024.
• Over 5 years, Share-based Compensation stood at -$22.4 million in 2021, then plunged by 39.29% to -$31.1 million in 2022, then jumped by 86.66% to -$4.2 million in 2023, then jumped by 1046.33% to $39.3 million in 2024, then plunged by 158.44% to -$23.0 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered -$23.0 million, $14.7 million, and $10.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.